Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Hookipa Pharma Inc (HOOK)
NASDAQ:HOOK
Holding HOOK?
Track your performance easily
HOOK Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.62 - $11.31
Previous Close$2.72
Volume171.84K
Average Volume (3M)36.86K
Market Cap
$27.61M
Enterprise Value-$29.32M
Total Cash (Recent Filing)$59.75M
Total Debt (Recent Filing)$2.83M
Price to Earnings (P/E)―
Beta1.55
Next Earnings
Mar 20, 2025EPS Estimate
-$0.93Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.99
Shares Outstanding12,054,539
10 Day Avg. Volume77,937
30 Day Avg. Volume36,862
Standard Deviation0.22
R-Squared0.04
Alpha-0.04
Financial Highlights & Ratios
Price to Book (P/B)0.46
Price to Sales (P/S)0.67
Price to Cash Flow (P/CF)-0.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-0.59
Enterprise Value/Gross Profit-1.46
Enterprise Value/Ebitda0.70
Forecast
1Y Price Target
$7.00Price Target Upside204.35% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Hookipa Pharma News
PremiumCompany Announcements
Hookipa Pharma Reports Q3 Earnings Amid Strategic ChangesBulls Say, Bears Say
Bulls Say
Clinical Trial ProgressThe ongoing Phase 1/2 has completed enrollment well in advance of plan, and updated results continued to highlight the potential superior results for eseba-vec + Keytruda vs. Keytruda monotherapy.
Financial PerformanceHookipa reported 3Q results demonstrating the impact of its cost-cutting efforts, beating consensus estimates.
Strategic PartnershipsHookipa is eligible for up to $185M in additional development and commercialization milestone payments, plus tiered royalties on net sales.
Bears Say
Safety ConcernsThere was a new death attributed to therapy, with the subject experiencing fulminant hepatitis while being treated with eseba-vec and Keytruda.
Stock PerformanceHookipa shares have generally moved lower following the ASCO abstract release, likely on competitor results.
Therapy ResultsThe ORR slipped somewhat from the 43% in the abstract as one PR was not confirmed.
---
Ownership Overview
3.50% Insiders
2.54% Mutual Funds
21.86% Other Institutional Investors
69.56% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
HOOK FAQ
What was Hookipa Pharma Inc’s price range in the past 12 months?
Hookipa Pharma Inc lowest stock price was $2.62 and its highest was $11.31 in the past 12 months.
What is Hookipa Pharma Inc’s market cap?
Currently, no data Available
When is Hookipa Pharma Inc’s upcoming earnings report date?
Hookipa Pharma Inc’s upcoming earnings report date is Mar 20, 2025 which is in 119 days.
How were Hookipa Pharma Inc’s earnings last quarter?
Hookipa Pharma Inc released its earnings results on Nov 14, 2024. The company reported -$1.1 earnings per share for the quarter, beating the consensus estimate of -$1.28 by $0.18.
Is Hookipa Pharma Inc overvalued?
According to Wall Street analysts Hookipa Pharma Inc’s price is currently Undervalued.
Does Hookipa Pharma Inc pay dividends?
Hookipa Pharma Inc does not currently pay dividends.
What is Hookipa Pharma Inc’s EPS estimate?
Hookipa Pharma Inc’s EPS estimate is -$0.93.
How many shares outstanding does Hookipa Pharma Inc have?
Hookipa Pharma Inc has 9,655,022 shares outstanding.
What happened to Hookipa Pharma Inc’s price movement after its last earnings report?
Hookipa Pharma Inc reported an EPS of -$1.1 in its last earnings report, beating expectations of -$1.28. Following the earnings report the stock price went down -4.459%.
Which hedge fund is a major shareholder of Hookipa Pharma Inc?
Among the largest hedge funds holding Hookipa Pharma Inc’s share is Baker Bros Advisors LP. It holds Hookipa Pharma Inc’s shares valued at 3M.
---
Hookipa Pharma Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$7.00 (204.35% Upside)
$7.00 (204.35% Upside)
Blogger Sentiment
Bullish
HOOK Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 960.0 Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.3%
Last 30 Days ▼ 7.3%
Last 30 Days ▼ 7.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-46.35%
12-Months-Change
Fundamentals
Return on Equity
-51.99%
Trailing 12-Months
Asset Growth
-33.10%
Trailing 12-Months
Company Description
Hookipa Pharma Inc
HOOKIPA Pharma, Inc. engages in the development of immunotherapeutics, targeting infectious diseases and cancers based on its proprietary its arenavirus platform that is designed to reprogram the body's immune system. Its product include VaxWace, a replication-deficient viral vector; and TheraT, a replication-attenuated viral vector, are designed to induce robust antigen specific CD8+ T cells and pathogen-neutralizing antibodies. The company was founded by Rolf Zinkernagel, Andreas Bergthaler, Lukas Flatz, and Daniel Pinschewer in 2011 and is headquartered in New York, NY.
---
HOOK Company Deck
---
HOOK Earnings Call
Q4 2023
0:00 / 0:00
---
HOOK Stock 12 Month Forecast
Average Price Target
$7.00
▲(204.35% Upside)
Technical Analysis
Best Analysts Covering HOOK
1 Year
1 Year Success Rate
2/24 ratings generated profit
1 Year Average Return
-46.29%
reiterated a buy rating 6 months ago
Copying Brian Abrahams's trades and holding each position for 1 Year would result in 8.33% of your transactions generating a profit, with an average return of -46.29% per trade.
---